Gilead Sciences Inc

Latest articles

1d
Business Wire
Global Cystic Fibrosis Therapeutics Market Outlook 2022boost the growth of cystic fibrosis therapeutics market. The report covers the
Business Wire / Posted yesterday
boost the growth of cystic fibrosis therapeutics market. The report covers the profiles of key players like Genentech, Inc. (A Member of the Roche Group), Novartis, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Gilead Sciences,... Read more
1d
Income Investors
3 Companies That Could Start to Pay Dividends in 2018through dividends, so of course retail and institutional investors love owning
Income Investors / Posted yesterday
through dividends, so of course retail and institutional investors love owning dividend-paying stocks, both for the income and the compounding returns. Dividends get passed on to shareholders from corporate earnings generated through daily... Read more
2d
Kansas City InfoZine
FDA Approves Vosevi for Hepatitis Call patients for evidence of current or prior HBV infection before starting tre
Kansas City InfoZine / Posted 2 days ago
all patients for evidence of current or prior HBV infection before starting treatment with Vosevi. The FDA granted this application Priority Review and Breakthrough Therapy designations. The FDA granted approval of Vosevi to Gilead Scienc... Read more
3 related articles
2d
New Kerala
Myovant Bolsters Executive Team with Key Management Appointments - newkerala news #255632BASEL, Switzerland, July 19, 2017 : Myovant Sciences (NYSE: MYOV) today announc
New Kerala / Posted 2 days ago
BASEL, Switzerland, July 19, 2017 : Myovant Sciences (NYSE: MYOV) today announced that it has strengthened its executive team through the appointment of four key management hires. Matthew Lang, JD, has joined the company as General Counsel and... Read more
3d
News-Medical-Net
FDA approves fixed-dose combination tablet for treating adults with chronic hepatitis Call patients for evidence of current or prior HBV infection before starting tre
News-Medical-Net / Posted 3 days ago
all patients for evidence of current or prior HBV infection before starting treatment with Vosevi. The FDA granted this application Priority Review and Breakthrough Therapy designations. The FDA granted approval of Vosevi to Gilead Scienc... Read more
3 related articles
4d
Channel NewsAsia
FDA approves Gilead's drug for chronic hep C patientsREUTERS: Gilead Sciences Inc said on Tuesday that the U.S. Food and Drug Admini
Channel NewsAsia / Posted 4 days ago
REUTERS: Gilead Sciences Inc said on Tuesday that the U.S. Food and Drug Administration approved its hepatitis C drug for patients who had failed to respond to prior treatments. Vosevi is the first drug to be approved for hepatitis C patients... Read more
9d
Market Watch
Fund manager with 20% gain this year sees good times ahead as FDA becomes ‘more accommodating’Bakri discussed was “investing in companies that advance the standard of care i
Market Watch / Posted 9 days ago
Bakri discussed was “investing in companies that advance the standard of care in an area of medicine with an unmet need.” Gilead Sciences Inc. GILD, +0.65% is a good example, he said, pointing to the success of its Harvoni hepatitis C medication.... Read more
10d
Business Wire
Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) anno
Business Wire / Posted 10 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2017 financial results will be released on Wednesday, July 26, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management... Read more
14d
FOX Business
What's Behind Gilead Sciences, Inc.'s 9.5% Rally in JuneWhat happened Shares of Gilead Sciences, Inc.(NASDAQ: GILD), a big biotech bes
FOX Business / Posted 14 days ago
What happened Shares of Gilead Sciences, Inc.(NASDAQ: GILD), a big biotech best known for its HIV and hepatitis treatments, perked up 9.53% in June according to data from S&P Global Market Intelligence. Investors viewed a draft of an executive order... Read more
14d
FOX Business
What's Behind Gilead Sciences, Inc.'s 9.5% Rally in JuneWhat happened Continue Reading Below Shares of Gilead Sciences, Inc.(NASDAQ:
FOX Business / Posted 14 days ago
What happened Continue Reading Below Shares of Gilead Sciences, Inc.(NASDAQ: GILD), a big biotech best known for its HIV and hepatitis treatments, perked up 9.53% in June according to data from S&P Global Market Intelligence. Investors viewed a... Read more
17d
Market Watch
Fund manager profited from tech, says now is time to focus on health-care sectorand trades for 15.8 times consensus 2018 earnings estimates. Asked to name his
Market Watch / Posted 17 days ago
and trades for 15.8 times consensus 2018 earnings estimates. Asked to name his favorite health-care stock, Dodson called Gilead Sciences Inc. GILD, +0.32% “a good one” that has “traded much higher.” The stock’s price is down 39% over the past two... Read more
29d
First Coast News
Study: Jacksonville area has ninth-highest rate of new HIV diagnoses in U.S.the lead investigator for AIDSVu, a project of Emory University’s Rollins Schoo
First Coast News / Posted 29 days ago
the lead investigator for AIDSVu, a project of Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc. AIDSVu this week released new interactive maps illustrating the impact of HIV across the United... Read more
30d
The Florida Times-Union
Study: Jacksonville area has ninth-highest rate of new HIV diagnoses in U.S.the lead investigator for AIDSVu, a project of Emory University’s Rollins Schoo
The Florida Times-Union / Posted 30 days ago
the lead investigator for AIDSVu, a project of Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc. AIDSVu this week released new interactive maps illustrating the impact of HIV across the United... Read more

In this news